BRIEF-Ziopharm Oncology Says Effective Dec 28, 2021 Co, As Borrower, Entered First Amendment To Loan, Security Agreement, Dated August 6, 2021

Reuters

Jan 05, 2022

Jan 4 (Reuters) - ZIOPHARM Oncology Inc :

* ZIOPHARM ONCOLOGY - EFFECTIVE DEC 28, 2021, CO, AS BORROWER, ENTERED FIRST AMENDMENT TO LOAN, SECURITY AGREEMENT, DATED AUGUST 6, 2021

* ZIOPHARM ONCOLOGY - AMENDED AGREEMENT EXTENDS INTEREST-ONLY PERIOD THROUGH AUGUST 31, 2022

* ZIOPHARM - AMENDMENT PROVIDES FOR EXTENSION OF INTEREST-ONLY PERIOD THROUGH AUG 31, 2023, IF, ON/PRIOR TO AUG 31, 2022 CO MEETS AMENDED MILESTONES

* ZIOPHARM ONCOLOGY - AMENDMENT REMOVES TERM B TRANCHE, WHICH REMAINED UNFUNDED, LEAVING ONLY TERM A TRANCHE

* ZIOPHARM -AMENDMENT PROVIDES TERM LOAN WILL MATURE ON AUG 1, 2023; PROVIDED, CO ACHIEVES MILESTONES ON/PRIOR TO AUG 31, 2022 FOR EXTENTION OF MATURITY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2201528814"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2201528814\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2201528814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-05 05:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2201528814","market":"us","top_or_hot":-1,"title":"BRIEF-Ziopharm Oncology Says Effective Dec 28, 2021 Co, As Borrower, Entered First Amendment To Loan, Security Agreement, Dated August 6, 2021","media":"Reuters","content":"<html><body><p>Jan 4 (Reuters) - <a href=\"https://laohu8.com/S/ZIOP\">ZIOPHARM Oncology Inc</a>   :</p><p>   * ZIOPHARM ONCOLOGY - EFFECTIVE DEC 28, 2021, CO, AS BORROWER, ENTERED FIRST AMENDMENT TO LOAN, SECURITY AGREEMENT, DATED AUGUST 6, 2021</p><p>   * ZIOPHARM ONCOLOGY - AMENDED AGREEMENT EXTENDS INTEREST-ONLY PERIOD THROUGH AUGUST 31, 2022</p><p>   * ZIOPHARM - AMENDMENT PROVIDES FOR EXTENSION OF  INTEREST-ONLY PERIOD THROUGH AUG 31, 2023, IF, ON/PRIOR TO AUG 31, 2022 CO MEETS AMENDED MILESTONES</p><p>   * ZIOPHARM ONCOLOGY - AMENDMENT REMOVES TERM B TRANCHE, WHICH REMAINED UNFUNDED, LEAVING ONLY TERM A TRANCHE</p><p>   * ZIOPHARM -AMENDMENT PROVIDES TERM LOAN WILL MATURE ON AUG 1, 2023; PROVIDED, CO ACHIEVES MILESTONES ON/PRIOR TO AUG 31, 2022 FOR EXTENTION OF MATURITY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ziopharm Oncology Says Effective Dec 28, 2021 Co, As Borrower, Entered First Amendment To Loan, Security Agreement, Dated August 6, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ziopharm Oncology Says Effective Dec 28, 2021 Co, As Borrower, Entered First Amendment To Loan, Security Agreement, Dated August 6, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-05 05:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 4 (Reuters) - <a href=\"https://laohu8.com/S/ZIOP\">ZIOPHARM Oncology Inc</a>   :</p><p>   * ZIOPHARM ONCOLOGY - EFFECTIVE DEC 28, 2021, CO, AS BORROWER, ENTERED FIRST AMENDMENT TO LOAN, SECURITY AGREEMENT, DATED AUGUST 6, 2021</p><p>   * ZIOPHARM ONCOLOGY - AMENDED AGREEMENT EXTENDS INTEREST-ONLY PERIOD THROUGH AUGUST 31, 2022</p><p>   * ZIOPHARM - AMENDMENT PROVIDES FOR EXTENSION OF  INTEREST-ONLY PERIOD THROUGH AUG 31, 2023, IF, ON/PRIOR TO AUG 31, 2022 CO MEETS AMENDED MILESTONES</p><p>   * ZIOPHARM ONCOLOGY - AMENDMENT REMOVES TERM B TRANCHE, WHICH REMAINED UNFUNDED, LEAVING ONLY TERM A TRANCHE</p><p>   * ZIOPHARM -AMENDMENT PROVIDES TERM LOAN WILL MATURE ON AUG 1, 2023; PROVIDED, CO ACHIEVES MILESTONES ON/PRIOR TO AUG 31, 2022 FOR EXTENTION OF MATURITY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2201528814","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2201528814","pubTimestamp":1641331340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 4 (Reuters) - ZIOPHARM Oncology Inc   :   * ZIOPHARM ONCOLOGY - EFFECTIVE DEC 28, 2021, CO, AS B","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"简介-Ziopharm肿瘤学表示，自2021年12月28日生效，公司作为借款人，于2021年8月6日加入了贷款第一修正案，担保协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZIOP":0.9},"content_text":"Jan 4 (Reuters) - ZIOPHARM Oncology Inc   :   * ZIOPHARM ONCOLOGY - EFFECTIVE DEC 28, 2021, CO, AS BORROWER, ENTERED FIRST AMENDMENT TO LOAN, SECURITY AGREEMENT, DATED AUGUST 6, 2021   * ZIOPHARM ONCOLOGY - AMENDED AGREEMENT EXTENDS INTEREST-ONLY PERIOD THROUGH AUGUST 31, 2022   * ZIOPHARM - AMENDMENT PROVIDES FOR EXTENSION OF  INTEREST-ONLY PERIOD THROUGH AUG 31, 2023, IF, ON/PRIOR TO AUG 31, 2022 CO MEETS AMENDED MILESTONES   * ZIOPHARM ONCOLOGY - AMENDMENT REMOVES TERM B TRANCHE, WHICH REMAINED UNFUNDED, LEAVING ONLY TERM A TRANCHE   * ZIOPHARM -AMENDMENT PROVIDES TERM LOAN WILL MATURE ON AUG 1, 2023; PROVIDED, CO ACHIEVES MILESTONES ON/PRIOR TO AUG 31, 2022 FOR EXTENTION OF MATURITYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}